Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/219735
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

AuthorsGarmendia, Irati; Pajares, María J.; Hermida-Prado, Francisco; Ajona, Daniel; Bértolo, Cristina; Sainz, Cristina; Lavín, Amaya; Remírez, Ana B.; Valencia, Karmele; Moreno, Haritz; Ferrer, Irene; Behrens, Carmen; Cuadrado, Myriam; Paz-Ares, Luis CSIC ORCID; Bustelo, Xosé R. CSIC ORCID ; Gil-Bazo, Ignacio; Alameda, Daniel; Lecanda, Fernando; Calvo, Alfonso; Felip, Enriqueta; Sánchez-Céspedes, M.; Wistuba, Ignacio I.; Granda-Diaz, Rocio; Rodrigo, Juan Pablo; García-Pedrero, Juana María; Pio, Ruben; Montuenga, Luis M.; Agorreta, Jackeline
KeywordsDasatinib
Lung cancer
YES1
Src family kinases
Predictive biomarker
Issue Date2019
PublisherAmerican Thoracic Society
CitationAmerican Journal of Respiratory and Critical Care Medicine 200(7): 888-899 (2019)
Abstract[Rationale]: The characterization of new genetic alterations is essential to assign effective personalized therapies in non–small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers is essential for successful personalized therapies. Molecular alterations of YES1, a member of the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found in a significant subset of patients with lung cancer.
[Objectives]: To evaluate YES1 (v-YES-1 Yamaguchi sarcoma viral oncogene homolog 1) genetic alteration as a therapeutic target and predictive biomarker of response to dasatinib in NSCLC.
[Methods]: Functional significance was evaluated by in vivo models of NSCLC and metastasis and patient-derived xenografts. The efficacy of pharmacological and genetic (CRISPR [clustered regularly interspaced short palindromic repeats]/Cas9 [CRISPR-associated protein 9]) YES1 abrogation was also evaluated. In vitro functional assays for signaling, survival, and invasion were also performed. The association between YES1 alterations and prognosis was evaluated in clinical samples.
[Measurements and Main Results]: We demonstrated that YES1 is essential for NSCLC carcinogenesis. Furthermore, YES1 overexpression induced metastatic spread in preclinical in vivo models. YES1 genetic depletion by CRISPR/Cas9 technology significantly reduced tumor growth and metastasis. YES1 effects were mainly driven by mTOR (mammalian target of rapamycin) signaling. Interestingly, cell lines and patient-derived xenograft models with YES1 gene amplifications presented a high sensitivity to dasatinib, an SFK inhibitor, pointing out YES1 status as a stratification biomarker for dasatinib response. Moreover, high YES1 protein expression was an independent predictor for poor prognosis in patients with lung cancer.
[Conclusions]: YES1 is a promising therapeutic target in lung cancer. Our results provide support for the clinical evaluation of dasatinib treatment in a selected subset of patients using YES1 status as predictive biomarker for therapy.
Publisher version (URL)https://doi.org/10.1164/rccm.201807-1292OC
URIhttp://hdl.handle.net/10261/219735
DOI10.1164/rccm.201807-1292OC
ISSN1073-449X
E-ISSN1535-4970
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
yesdasati.pdf1,81 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

SCOPUSTM   
Citations

24
checked on May 22, 2022

WEB OF SCIENCETM
Citations

24
checked on May 19, 2022

Page view(s)

110
checked on May 22, 2022

Download(s)

128
checked on May 22, 2022

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.